Search results for "hazard"

showing 10 items of 1517 documents

Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long…

2020

Introduction: Surgical procedure is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable number of patients experience recurrence within the first 2 years after complete resection. Suitable prognostic biomarkers that identify patients at high risk of recurrence (who may probably benefit from adjuvant treatment) are still not available. This study aimed at identifying methylation markers for early recurrence that may become important tools for the development of new treatment modalities. Methods: Genome-wide DNA methylation profiling was performed on 30 stage I lung adenocarcinomas, comparing 14 patients with early metastatic recurrence with 16 patients with …

0301 basic medicinePulmonary and Respiratory MedicineOncologyLung adenocarcinomamedicine.medical_specialtyLung NeoplasmsADNAdenocarcinoma of LungMethylation profilingmedicine.disease_causeMethylation03 medical and health sciences0302 clinical medicinePrognostic markerPLUTInternal medicineBiomarkers TumorHumansMedicineddc:610Promoter Regions Geneticbusiness.industryHazard ratioPromoterMethylationDNADNA MethylationPrognosismedicine.diseaseLong non-coding RNA030104 developmental biologyDifferentially methylated regionsOncology030220 oncology & carcinogenesisIncRNACàncer de pulmóBiomarker (medicine)AdenocarcinomaRNA Long NoncodingNeoplasm Recurrence LocalLung cancerbusinessCarcinogenesisMetilació
researchProduct

Blood group antigen A type 3 expression is a favorable prognostic factor in advanced NSCLC.

2015

Abstract Objectives Several blood group-related carbohydrate antigens are prognosis-relevant markers of tumor tissues. A type 3 (repetitive A) is a blood group antigen specific for A 1 erythrocytes. Its potential expression in tumor tissues has so far not been examined. Material and methods We have evaluated its expression in normal lung and in lung cancer using a novel antibody (A69-A/E8). For comparison an anti-A antibody specific to A types 1 and 2 was used, because its expression on lung cancer tissue has been previously reported to be of prognostic relevance. Resected tissue samples of 398 NSCLC patients were analyzed in immunohistochemistry using tissue microarrays. Results and conclu…

0301 basic medicinePulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPathologyLung Neoplasms03 medical and health sciences0302 clinical medicineAntigenAntigens NeoplasmInternal medicineCarcinoma Non-Small-Cell LungmedicineBiomarkers TumorHumansLung cancerProspective cohort studyAgedTissue microarrayLungbiologyProportional hazards modelbusiness.industrymedicine.diseasePrognosisImmunohistochemistrySurvival Analysisrespiratory tract diseases030104 developmental biologymedicine.anatomical_structureOncologyTissue Array Analysis030220 oncology & carcinogenesisbiology.proteinBlood Group AntigensImmunohistochemistryFemaleAntibodybusinessLung cancer (Amsterdam, Netherlands)
researchProduct

Outcome of liver transplantation for hepatopulmonary syndrome: a Eurotransplant experience.

2019

Hepatopulmonary syndrome (HPS) is a pulmonary vascular complication of liver disease that affects up to 30% of patients with cirrhosis [1]. Intrapulmonary vascular dilatations and shunts result in gas exchange abnormalities, ranging from elevated alveolar-arterial oxygen gradients with no hypoxemia to very severe hypoxemia [1, 2]. Currently, liver transplantation (LT) is the only treatment option [3]. The Model for End-Stage Liver Disease (MELD) is a scoring system for assessing liver disease severity that has been validated to predict the 3-months waitlist mortality, and is used by Eurotransplant for prioritising allocation of liver transplants [4]. Footnotes This manuscript has recently b…

0301 basic medicinePulmonary and Respiratory MedicineRiskScoring systemmedicine.medical_treatmentMedizinVascular complicationLiver transplantationEnd Stage Liver Disease03 medical and health sciences0302 clinical medicineSevere hypoxemiaNothingMedicineHumansRegistriesProportional Hazards ModelsRetrospective Studiesbusiness.industryConflict of interestTreatment optionsLiver TransplantationEuropeOxygen030104 developmental biologyTreatment OutcomeLaw030211 gastroenterology & hepatologybusinessProduction teamHepatopulmonary SyndromeThe European respiratory journal
researchProduct

Evaluation of viability PCR performance for assessing norovirus infectivity in fresh-cut vegetables and irrigation water

2016

Norovirus (NoV) detection in food and water is mainly carried out by quantitative RT-PCR (RT-qPCR). The inability to differentiate between infectious and inactivated viruses and the resulting overestimation of viral targets is considered a major disadvantage of RT-qPCR. Initially, conventional photoactivatable dyes (i.e. propidium monoazide, PMA and ethidium monoazide, EMA) and newly developed ones (i.e. PMAxx and PEMAX) were evaluated for the discrimination between infectious and thermally inactivated NoV genogroup I (GI) and II (GII) suspensions. Results showed that PMAxx was the best photoactivatable dye to assess NoV infectivity. This procedure was further optimized in artificially inoc…

0301 basic medicineVirus inactivation030106 microbiologyReal-Time Polymerase Chain Reactionmedicine.disease_causeMicrobiologyIrrigation waterMicrobiology03 medical and health sciencesstomatognathic systemPropidium monoazideVegetablesmedicineFood scienceInfectivityMicrobial ViabilitybiologyInoculationNorovirusGeneral Medicinebiology.organism_classification030104 developmental biologyFoodNorovirusRNA ViralVirus InactivationSpinachWater MicrobiologyHazard Analysis and Critical Control PointsFood ScienceEthidium monoazideInternational Journal of Food Microbiology
researchProduct

Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

2020

AbstractBackgroundCurrently, no data are available on the burden of morbidity and mortality in people with HIV-1 (PWH) harboring a 4-class drug-resistant (4DR) virus (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, integrase strand transfer inhibitors). The study aimed to assess the incidence of clinical events and death in this population.MethodsThis was a cohort study on PWH from the PRESTIGIO Registry with a documented 4DR virus. Burden of disease was defined as the occurrence of any new event including an AIDS-defining event (ADE) or non-AIDS-defining event (NADE) or death from any cause after 4DR evidence (baseline). Co…

0301 basic medicinemedicine.medical_specialty4-class drug resistance; AIDS-defining event; cancer; death; non-AIDS-defining event4-class drug resistancenon-AIDS-defining event.PopulationMajor ArticlesSettore MED/0703 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinedeathmedicinecancerCumulative incidenceAIDS-defining event030212 general & internal medicineeducationnon-AIDS-defining eventDisease burdeneducation.field_of_studyProportional hazards modelbusiness.industryIncidence (epidemiology)Hazard ratio030112 virologyAcademicSubjects/MED00290Infectious DiseasesOncologybusinessCohort study
researchProduct

Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study

2016

Introduction Stratification for subsequent coronary events among patients with coronary artery disease (CAD) is of considerable interest because of the potential to guide secondary preventive therapies. Recently, we identified eight microRNAs (miRNAs), which facilitated acute coronary syndrome (ACS) diagnosis. In this study, we aimed to evaluate their potential role as prognostic biomarkers for cardiovascular disease. Methods The serum concentrations of eight candidate miRNAs -miR-19a, miR-19b, miR-132, miR-140-3p, miR-142-5p, miR-150, miR-186, and miR-210 were measured in a cohort of 1112 patients with documented CAD—including 430 patients with ACS and 682 patients with stable angina pecto…

0301 basic medicinemedicine.medical_specialtyAcute coronary syndromePathologyProportional hazards modelbusiness.industryDisease030204 cardiovascular system & hematologymedicine.diseaseCoronary artery disease03 medical and health sciencesCirculating MicroRNA030104 developmental biology0302 clinical medicineInternal medicineCohortmedicineCardiologyBiomarker (medicine)Cardiology and Cardiovascular MedicineRisk assessmentbusinessEuropean Heart Journal
researchProduct

Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine…

2018

Background. High neutrophil to lymphocyte ratio (NLR) has shown to be a predictor of poor outcomes in various malignancies, including pancreatic cancer. Methods. We assessed 70 consecutive pts with histologically confirmed mPC who received chemotherapy with nab-paclitaxel/gemcitabine at two different European oncologic centers between January 2012 and November 2015. Variables assessed for prognostic correlations included age ≥ 66, sex, Karnofsky PS score, primary tumor site, baseline CA19.9 level ≥ 59xULN, 12-week decrease of the CA19.9 level ≥ 50% from baseline, basal bilirubin level, baseline NLR, biliary stent implantation, and liver metastasis. Survival analyses were generated according…

0301 basic medicinemedicine.medical_specialtyArticle Subjectmedicine.medical_treatmentGastroenterologyMetastasis03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancermedicineNeutrophil to lymphocyte ratiolcsh:RC799-869ChemotherapyHepatologyProportional hazards modelbusiness.industryGastroenterologymedicine.diseasePrimary tumorGemcitabine030104 developmental biology030220 oncology & carcinogenesisPropensity score matchinglcsh:Diseases of the digestive system. Gastroenterologybusinessmedicine.drugResearch ArticleGastroenterology Research and Practice
researchProduct

Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or me…

2020

Background Palliative chemotherapy of advanced oesophageal squamous cell cancer (ESCC) consists of cisplatin/5-fluorouracil (CF) to target epidermal growth factor receptor (EGFR) with panitumumab (P); chemotherapy enhanced overall survival (OS) in advanced colorectal or squamous cell head and neck cancers. With prospective serum and tumour biomarkers, we tested if P added to CF (CFP) improved OS in advanced ESCC. Patients and methods Eligible patients with confirmed ESCC that was not curatively resectable or did not qualify for definitive radiochemotherapy, were randomised 1 : 1 to receive CF [cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1–4] or CF plus P (9…

0301 basic medicinemedicine.medical_specialtyEsophageal Neoplasmsmedicine.medical_treatmentPopulationMedizinGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicinePanitumumabHumansProspective StudieseducationCisplatineducation.field_of_studyChemotherapybusiness.industryPanitumumabHazard ratioCommon Terminology Criteria for Adverse EventsHematologymedicine.diseaseErbB Receptors030104 developmental biologyTreatment OutcomeOncologyFluorouracil030220 oncology & carcinogenesisCarcinoma Squamous CellFluorouracilCisplatinbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Longevity and risk factors of post restorations after up to 15 years: A practice-based study.

2020

Abstract Introduction The aims of this multicenter, practice-based cohort study were to evaluate the success and survival of endodontically treated teeth with post restorations (ETT+Ps) and to analyze factors associated with the longevity of ETT+Ps. Methods Eight general dental practitioners each placed up to 27 ETT+Ps without any restriction to post materials or dimensions. Only incisors, canines, and premolars were included. At the last follow-up visit, ETT+Ps were considered as successful if the post and the initially placed definitive restoration were sufficient, whereas ETT+Ps were considered as survived if the post was still in function. Multilevel Cox proportional hazards models were…

0301 basic medicinemedicine.medical_specialtyMultivariate analysisDentistsDentistryComposite ResinsCohort Studies03 medical and health sciencesProfessional Role0302 clinical medicineRisk FactorsmedicineHumansDental Restoration FailureDental Restoration Permanent610 Medicine & healthGeneral DentistryRetrospective StudiesTooth NonvitalCrownsbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryEndodonticsConfidence interval030104 developmental biologyPrivate practiceGeneral practicebusinessPost and Core TechniqueCohort study
researchProduct

Impact of Donor-Recipient Histocompatibility and CMV-Mismatch on Outcome of Allogeneic Stem Cell Transplantation for AML and MDS: A Retrospective Reg…

2016

Abstract Introduction Allogeneic stem cell transplantation (allo-SCT) is a curative treatment for several hematological diseases. Donor-recipient histo-incompatibility is associated with poorer outcome. Transplant outcome of CMV positive patients is reported to be poorer, if the unrelated donor is CMV negative (CMV-mismatch). Recent developments in transplant strategies including high resolution HLA-typing, toxicity-reduced conditioning regimens, CMV-monitoring, and improved supportive care have made transplants from HLA- as well as CMV- mismatched unrelated donors more feasible. We present a retrospective registry analysis from a large, and recent cohort of patients transplanted under thes…

0301 basic medicinemedicine.medical_specialtyProportional hazards modelbusiness.industryDonor selectionImmunologySubgroup analysisCell BiologyHematologyHuman leukocyte antigenBiochemistrySurgeryHistocompatibilityTransplantation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisInternal medicineCohortmedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct